4.7 Review

Clinical features, pathophysiology, and treatment of medication-overuse headache

Journal

LANCET NEUROLOGY
Volume 9, Issue 4, Pages 391-401

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(10)70008-9

Keywords

-

Funding

  1. Addex
  2. AGA Medical
  3. Allergan
  4. Berlin-Chemie
  5. Boehringer
  6. CoLucid
  7. Eisai
  8. GlaxoSmithKline
  9. Janssen-Cilag
  10. Merck
  11. Novartis
  12. Pfizer
  13. Reckitt-Benckise
  14. UCB
  15. MSD
  16. Solvay
  17. Teva
  18. Bayer Schering Pharma
  19. Biogen Idec
  20. Sanofi-Aventis
  21. Merck Serono

Ask authors/readers for more resources

Medication-overuse headache (MOH) is a chronic headache disorder defined by the International Headache Society as a headache induced by the overuse of analgesics, triptans, or other acute headache compounds. The population-based prevalence of MOH is 0.7% to 1.7%. Most patients with MOH have migraine as their primary headache and overuse triptans or simple analgesics. The pathophysiology of MOH is still unknown. As well as psychological mechanisms such as operant conditioning, changes in endocrinological homoeostasis and neurophysiological changes have been observed in patients with MOH. Recently, a genetic susceptibility has been postulated. In most cases, treatment of MOH consists of abrupt withdrawal therapy and then initiation of an appropriate preventive drug therapy. There is no clear evidence on which method of withdrawal therapy is the most efficacious. Withdrawal symptoms can be treated with steroids; however, not all data support this concept. As MOH can severely affect the quality of life of patients, it needs to be recognised early to enable appropriate treatment to be initiated.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available